On October 31, 2023, the team led by Prof. Yu Bo at the Second Affiliated Hospital of Harbin Medical  University successfully utilized HighLife® TSMVR system for a patient with severe functional mitral  regurgitation (MR) through the femoral vein. Under the guidance of Prof. Yu Bo, the cardiology department  collaborated with a multidisciplinary team. Immediate ultrasound assessment indicated complete  disappearance of MR, no paravalvular leakage (PVL), ideal positioning of the prosthetic valve, good  morphology, and a well-functioning left ventricular outflow tract (LVOT). The valve implantation was  successful, and the patient recovered stably postoperatively with significant improvement in hemodynamics.  The patient has been discharged safely.

TSMVR remains in the forefront of global exploration currently. This experience signifies a significant step  forward for the Second Affiliated Hospital of Harbin Medical University in the international exploration of  cutting-edge technologies in the field of interventional therapy of structural heart disease. It contributes to  validating the feasibility and ease of use of the HighLife® TSMVR system under standardized procedures. As  the clinical trial progresses in China, it will continue to promote the dissemination and development of  HighLife® TSMVR system.